AI in healthcare statistics (2026)

"How much has AI actually changed healthcare?" gets answered with whichever number is closest to hand — and the numbers rarely agree, because they rarely measure the same thing. This page is the hub for our statistics cluster: the dozen-or-so figures that carry the most weight, each pinned to a primary source, dated, and labelled with what it really counts. Four questions organize it — who is using AI, what the evidence shows, what the rules now require, and where the money went. As of August 2026.

How to read a healthcare-AI statistic

One habit prevents most confusion: ask what the denominator is. An adoption figure can count clinicians offered a tool, clinicians who used it once, or clinicians who use it for most of their visits — three very different populations behind the same percent sign. A device count depends on whether "AI" means any authorization mentioning the term or a narrower technical definition. Every figure below is written to make its denominator and its date visible, because a stat without those two things is closer to a slogan than a measurement.

Adoption — who is using AI?

The clearest adoption signal comes from the American Medical Association's Augmented Intelligence survey, now three waves deep. In the 2026 wave — 1,692 US physicians, fielded 15 January–2 February 2026 — 72% reported incorporating at least one AI use case into their practice, up from 48% in 2024 and 38% in 2023; the broader 81% headline adds the 9% who are aware of AI in their practice but unsure which tools it offers 1. Use is compounding as well as spreading: the average user now runs 2.3 use cases, up from 1.1 in 2023, led by summaries of research and standards of care at 39% 1. Sentiment climbed more slowly than adoption: 76% see an advantage to patient care (65% in 2023, 69% in 2024), while the share more excited than concerned edged from 30% to just 37%, and 40% remain evenly split 1. The mid-series reading held the same shape — in the 2024 wave, 66% reported using AI, double the 38% of 2023 14.

That enthusiasm is conditional. The same physicians named what would move them further: safety and efficacy validated by a trusted entity (88% rate it important), data-privacy assurances (86%), and clear liability frameworks — ranked the single most important regulatory action, placed first by 31% 1. The appetite is real; the trust is contingent. Our physician attitudes tracker holds the wave-by-wave detail, including the instrument changes that make the headline series only partly comparable.

How far has AI reached the clinic?

Two very different measures show how far AI has actually reached the clinic.

On the device side, a peer-reviewed taxonomy examined 1,016 FDA authorizations of AI-enabled devices and found that quantitative image analysis remains the most common function, though its relative share is now declining; more than 100 devices use AI to generate data, and none yet rely on large language models 2. The distribution is lopsided by specialty: of the 168 machine-learning-enabled devices the FDA authorized in 2024, 74.4% (125) were radiology, trailed distantly by cardiovascular (6.5%) and neurology (6.0%) 3. The FDA's own device list is the living record here 13; our FDA device tracker breaks the trend down by year and panel.

On the software-in-workflow side, the largest documented rollout is the ambient AI scribe at The Permanente Medical Group. In its first ten weeks, 3,442 physicians used it across 303,266 encounters 5; one year in, the group reported the tool had passed over 2.5 million uses 4. That is the ceiling of what a well-resourced deployment looks like — most systems report pilots. Our AI scribe adoption tracker keeps the running tally.

Evidence — what do the studies show?

Adoption without outcomes is just enthusiasm, so the controlled evidence matters more than the headline counts.

Two patterns run through the table. First, the documentation-relief story is consistent but modest — real minutes back, not transformed days, and uneven because only about a third of clinicians use the tool for most visits 6. Second, the strongest clinical-outcome signal is where AI acts as a second set of eyes on an image or a video: pooling 12 randomized trials, computer-aided colonoscopy raised the adenoma detection rate from 33% to 41.4% 8. Benchmark scores like the 86.1% on a USMLE-style question set 9 show what a model can do on an exam — not what it does in a clinic, which is a different and harder measurement. Our clinical trial results tracker and LLM benchmark tracker hold the deeper reads.

Regulation — what do the rules now require?

The rulebook filled in quickly across 2024 — and then its calendar moved. The EU AI Act (Regulation 2024/1689) entered into force on 1 August 2024 and reached its general application date on 2 August 2026 10. But the high-risk obligations that matter most to healthcare no longer arrive on the dates first enacted: the Digital Omnibus, in force since 27 July 2026, deferred them. Standalone high-risk systems under Annex III — including healthcare-eligibility and emergency-triage AI — now fall due on 2 December 2027, and AI that is a regulated medical device, high-risk via Annex I, now falls due on 2 August 2028 15. Our living EU AI Act timeline tracks both routes date by date. In parallel, the World Health Organization issued dedicated guidance on large multi-modal models in health in January 2024, carrying more than 40 recommendations for governments, developers, and providers 11. Alongside both, the FDA's device list and its evolving change-control expectations remain the operational reference for anything marketed in the US 13. The global regulation tracker follows each milestone.

Investment — where did the money go?

Capital has concentrated hard around the label. US digital-health startups raised $14.2B in 2025 — a 35% rise over 2024 — and companies marketing AI took 54% of those dollars, up from 37% the year before, with larger average rounds than their non-AI peers 12. The concentration is the story as much as the total: a handful of very large raises pulled the annual figure up. Our funding and M&A tracker keeps the series current.

How to read these numbers

Four cautions travel with everything above. Adoption percentages hide their denominators — being offered a tool, trying it once, and depending on it daily are not the same fact. Device counts depend on inclusion criteria and the date the list was pulled, so two credible sources can report different totals for the same agency. Controlled effects are consistently smaller than the ones users describe from memory. And a benchmark score is a laboratory result rather than a clinical one. Treat each figure as a reading with an error bar, never a verdict.

Sources and method

Every figure here is dated and tied to a numbered primary source below — regulator pages, peer-reviewed studies, an official physician survey, and a named funding tracker. Where a headline circulates without a first-party source, we leave it out. We refresh this hub on a 90-day cycle and whenever the FDA list, the AMA survey, a major funding report, or an EU AI Act milestone changes — this page was refreshed on 16 August 2026 after the AMA's March 2026 survey wave and the Digital Omnibus deferral satisfied two of those triggers. If you found this through a single stat, the sibling trackers linked throughout carry the depth behind it.